Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02173171 · ClinicalTrials.gov registry record
Registry Study for Talimogene Laherparepvec
A clinical trial of Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial, sponsored by Amgen.
- Completed
- Registry status
- 185
- Enrollment target
- 20
- Study locations
NCT02173171 is a study of Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial that has completed, run by Amgen. The registered enrollment target is 185 participants. The trial reports 20 study locations across 15 states.
The verdict
NCT02173171, a study of Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- 185 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects Who Previously Received Talimogene Laherparepvec in Amgen or BioVEX-Sponsored Clinical Trials
Conditions Studied
Interventions
- OTHER Information collection
Study Locations (20)
Florida
- Florida Hospital Memorial Division - Daytona Beach
- Baptist MD Anderson Cancer Center - Jacksonville
- Mount Sinai Comprehensive Cancer Center - Miami Beach
- H Lee Moffitt Cancer Center and Research Institute - Tampa
New Jersey
- Morristown Medical Center - Morristown
- Rutgers Cancer Institute of New Jersey - New Brunswick
North Carolina
- University of North Carolina Chapel Hill - Chapel Hill
- Wake Forest Baptist Health Medical Center - Winston-Salem
Alabama
- University of South Alabama Mitchell Cancer Institute - Mobile
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
California
- St Joseph Heritage Healthcare - Santa Rosa
Colorado
- University of Colorado Cancer Center - Aurora
Illinois
- Oncology Specialists SC - Park Ridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 2010-04-27 |
| Est. Completion | 2021-09-23 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02173171
The ClinicalTrials.gov registry entry for NCT02173171 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 185 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial appearing as the primary indexed condition, and to 1 intervention - of which Information collection is the first listed.
NCT02173171 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Florida, New Jersey, North Carolina.
Frequently Asked Questions
What is clinical trial NCT02173171 about?
NCT02173171 is a clinical study titled "Registry Study for Talimogene Laherparepvec". A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects Who Previously Received Talimogene Laherparepvec in Amgen or BioVEX-Sponsored Clinical Trials
What is the current status of trial NCT02173171?
This trial is currently completed. The enrollment target is 185 participants. The study started on 2010-04-27. Estimated completion is 2021-09-23.
What conditions does trial NCT02173171 study?
This clinical trial studies the following conditions: Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial.
What interventions are being tested in trial NCT02173171?
The interventions under investigation include: Information collection (OTHER).
Who is sponsoring clinical trial NCT02173171?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02173171 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial
All registered trials for this condition
Alabama
All trials with a study site in Alabama
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.